Form 4: Vera Therapeutics CEO Sells Shares to Cover Tax Obligations

Vera Therapeutics CEO Marshall Fordyce sold 14,471 shares of Class A Common Stock on August 21, 2024, to cover tax withholding obligations.

Summary

• On August 21, 2024, Marshall Fordyce, the President and CEO of Vera Therapeutics, sold 14,471 shares of Class A Common Stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $39.764.
• Following the transaction, Fordyce directly owns 322,667 shares of Vera Therapeutics.
• The sale was made pursuant to a Rule 10b5-1(c) trading plan established on August 26, 2022.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a stock sale by the CEO to cover tax obligations, which is a routine transaction. The existence of a pre-arranged trading plan mitigates any negative implications.

Industry Context

Sales by company executives are a normal part of corporate governance. It is important to note that the sale was to cover tax obligations and was executed under a pre-arranged trading plan, which is a common practice to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the pre-arranged trading plan suggests it was not based on inside information.

Key Dates